Results 91 to 100 of about 3,006,184 (303)

Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function

Frontiers in Cell and Developmental Biology, 2017
Calreticulin is a Ca2+-binding chaperone protein, which resides mainly in the endoplasmic reticulum but also found in other cellular compartments including the plasma membrane. In addition to Ca2+, calreticulin binds and regulates almost all proteins and
Lilian Varricchio, Mario Falchi, Massimiliano Dall'Ora, Caterina De Benedittis, Alessandra Ruggeri, Vladimir N. Uversky, Vladimir N. Uversky, Anna Rita Migliaccio, Anna Rita Migliaccio   +8 more
doaj   +1 more source

Myeloproliferative masks of multiple myeloma: A review of literature and clinical case reports [PDF]

Терапевтический архив, 2017
Concurrences of multiple myeloma with myeloproliferative diseases or secondary myeloid leukemoid reactions are rather rare. The paper describes 3 cases of multiple myeloma: the first case concurrent with neutrophilic leukocytosis; the second case with ...
V V Ryzhko, A E Grachev, A A Klodzinsky, T V Ivanova, M S Sataeva, E O Gribanova   +5 more
doaj   +1 more source

Sex differences in the JAK2V617F allele burden in chronic myeloproliferative disorders

Haematologica, 2010
Background The JAK2V617F allele burden is a variable measure, determined by the frequency of mitotic recombination events and the expansion of JAK2V617F clones.
B. Stein, Donna M. Williams, Nae-Yuh Wang, O. Rogers, M. Isaacs, N. Pemmaraju, J. Spivak, A. Moliterno   +7 more
semanticscholar   +1 more source

Factors Affecting Immune Reconstitution Post‐Allogeneic HSCT in Children: The Case for an Individualized Approach to Vaccination

European Journal of Haematology, EarlyView.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is increasingly used to treat malignant and non‐malignant diseases. Following allogeneic HSCT, patients are particularly vulnerable to vaccine‐preventable diseases (VPD) because conditioning depletes immune cells, including memory cells.
Hélène Buvelot, Frederic Baleydier, Laure Pittet, Geraldine Blanchard‐Rohner   +3 more
wiley   +1 more source

JAK2 V617F Analysis in Indonesian Myeloproliferative Neoplasms Patients [PDF]

, 2015
Background : Three subtypes of myeloproliferative neoplasms (MPNs): Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) showed overlapping phenotype.
Faradz, S. M. (Sultana), Saktini, F. (Fanti), Santosa, S. (Santosa)   +2 more
core   +3 more sources

Polycythemia Vera and Essential Thrombocythemia: A Nationwide Population‐Based Study on Treatment Patterns, Vascular Complications and Survival

European Journal of Haematology, EarlyView.
ABSTRACT Background Polycythemia vera (PV) and essential thrombocythemia (ET) are associated with a well‐recognized increased risk of thrombotic events, bleeding, and all‐cause mortality, but the frequency of these outcomes during treatment has rarely been assessed in large cohorts.
Anneli Enblom Larsson, Henrik Renlund, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander   +5 more
wiley   +1 more source

Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms

Cancer Management and Research, 2010
Joseph Tripodi1, Ronald Hoffman1, Vesna Najfeld2, Rona Weinberg31The Myeloproliferative Disorders Program, Tisch Cancer Institute, Department of Medicine and 2Department of Medicine and Pathology, Mount Sinai School of Medicine, 3The Myeloproliferative ...
Joseph Tripodi, Ronald Hoffman, Vesna Najfeld, et al   +3 more
doaj  

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

PLoS ONE, 2020
The myeloproliferative neoplasms, polycythemia vera, essential thrombocytosis and primary myelofibrosis are hematopoietic stem cell disorders and share driver mutations that either directly activate the thrombopoietin receptor, MPL, or activate it ...
Jerry L Spivak, Akil Merchant, Donna M Williams, Ophelia Rogers, Wanke Zhao, Amy Duffield, Linda S Resar, Alison R Moliterno, Zhizhuang J Zhao   +8 more
doaj   +1 more source

Diagnosing Systemic Mastocytosis: State of the Art

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT With the advent of effective multikinase and selective tyrosine kinase inhibitors in systemic mastocytosis, diagnosing this rare disease has been critical to improving patient morbidity and mortality. This state‐of‐the‐art review interprets the international diagnostic criteria, including differences between the WHO 5th edition classification ...
Anton Rets, Tracy I. George
wiley   +1 more source

Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia

Journal of Blood Medicine, 2013
Violaine Havelange,1,2 Jean-Baptiste Demoulin1 1de Duve Institute, Université catholique de Louvain, Brussels, Belgium; 2Department of Hematology, Cliniques universitaires Saint-Luc, Université catholique de Louvain, Brussels, Belgium ...
Havelange V, Demoulin JB
doaj